Compare TV & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TV | PGEN |
|---|---|---|
| Founded | 1969 | 1998 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 1993 | N/A |
| Metric | TV | PGEN |
|---|---|---|
| Price | $2.91 | $4.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | $4.93 | ★ $7.67 |
| AVG Volume (30 Days) | 2.0M | ★ 5.2M |
| Earning Date | 02-20-2026 | 11-13-2025 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,246,959,081.00 | $6,309,000.00 |
| Revenue This Year | N/A | $342.78 |
| Revenue Next Year | N/A | $478.46 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 59.20 |
| 52 Week Low | $1.55 | $1.05 |
| 52 Week High | $3.36 | $5.23 |
| Indicator | TV | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 49.16 | 67.11 |
| Support Level | $2.88 | $4.01 |
| Resistance Level | $3.10 | $4.53 |
| Average True Range (ATR) | 0.13 | 0.31 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 9.00 | 93.59 |
Televisa is one of the leading telecommunication firms in Mexico. Its cable arm, Izzi, holds networks that pass 20 million Mexican homes and provide broadband service to nearly 6 million customers. The firm is also one of the largest pay-television providers in Mexico, with 4 million customers. Televisa owns Sky Mexico, the country's only satellite-TV provider, serving about 5 million customers. After merging its traditional media business into Univision, Grupo Televisa owns a 43% stake in combined entity TelevisaUnivision. Grupo Televisa spun off several smaller businesses, including magazine publishing, three of Mexico's professional soccer teams, and Azteca Stadium in February 2024, under the name Ollamani.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.